PHOTODYNAMIC THERAPY WITH HEMATOPORPHYRIN DERIVATIVE IN THE TREATMENT OF SUPERFICIAL TRANSITIONAL-CELL CARCINOMA OF THE BLADDER
PHOTODYNAMIC THERAPY WITH HEMATOPORPHYRIN DERIVATIVE IN THE TREATMENT OF SUPERFICIAL TRANSITIONAL-CELL CARCINOMA OF THE BLADDER
复制标题
DOI：
10.1056/nejm198711123172003
复制
发表时间：
1987-11-12
影响因子：
158.5
通讯作者：
QIAO, SJ
中科院分区：
文献类型：
--
作者：
PROUT, GR;LIN, CW;QIAO, SJ
光动力疗法涉及光诱导破坏含有光敏剂（例如血卟啉衍生物）的肿瘤。我们进行了一项合作研究，以评估这种疗法治疗膀胱浅表移行细胞癌的疗效。对 37 名患者进行了评估，并选择了 20 名患者进行治疗。总共治疗了 50 个乳头状肿瘤和 3 个原位癌区域。除两个肿瘤外，所有肿瘤均小于 2.5 厘米。治疗后三个月进行治疗反应和毒性评估。在审查活检材料后，对一名患者的初步诊断进行了修订，该患者未纳入分析。 19 名患者中有 9 名（47%）观察到所有肿瘤完全根除，包括原位癌患者。在这 19 名患者中的其余 10 名患者中，有 13 名肿瘤无法被根除（总体根除率为 50 名肿瘤中的 37 名 [74%]），但这 10 名患者中有 9 名的肿瘤大小、数量或两者均减少了 50% 或更多。我们的结论是，光动力疗法可用于治疗膀胱浅表移行细胞癌，但需要对照试验来确定其在癌症治疗中的地位。
Photodynamic therapy involves light-induced destruction of tumors containing a photosensitizer such as hematoporphyrin derivative. We conducted a collaborative study to evaluate the efficacy of this form of therapy in treating superficial transitional-cell carcinoma of the bladder. Thirty-seven patients were evaluated and 20 were selected for treatment. A total of 50 papillary tumors and 3 areas of carcinoma in situ were treated. All except two tumors were smaller than 2.5 cm. Assessments for treatment response and toxicity were carried out three months after treatment. The initial diagnosis of one patient was revised after the biopsy material was reviewed, and this patient was not included in the analysis. Complete eradication of all tumors was observed in 9 of 19 patients (47 percent), including those with carcinoma in situ. In the remaining 10 of these 19 patients, 13 tumors could not be eradicated (the overall eradication rate was 37 of 50 tumors [74 percent]), but 9 of the 10 patients had a reduction in tumor size, number, or both of 50 percent or more. We conclude that photodynamic therapy is useful in the treatment of superficial transitional-cell carcinoma of the bladder, but controlled trials will be required to define its place in the treatment of cancer.